JOSEPH EDELMAN
CIK 1164426 · last filed 2026-07-22
JOSEPH EDELMAN is a corporate insider who has filed 204 SEC Form 4 insider transactions across 49 companies since 2007. The most recent filing shows the insider was granted $165.0M of FRNM on Jul 22, 2026. Across all open-market trades the lifetime net is +$1.78B, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $746.3M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$746.30M
Companies
49
Total Filings
204
Lifetime Open-Market Net
$1.78B
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| FRNM | 10%+ Owner | 10,871,847 | — | — | $0 | 1 | 2026-07-22 |
| LONA | Director | — | $7.08 | — | $0 | 4 | 2026-07-10 |
| SLDB | Director | 73,107 | $8.00 | $584.9K | $120.44M | 5 | 2026-03-11 |
| LeonaBio, Inc. (ATHA) Delisted | Director | 329,756 | $6.92 | $2.28M | $51.30M | 9 | 2025-12-23 |
| ADGM | 10%+ Owner | — | $0.46 | — | $0 | 1 | 2025-10-22 |
| ACRV | 10%+ Owner | 3,104,139 | $1.51 | $4.70M | $48.71M | 3 | 2025-05-01 |
| ALDX | 10%+ Owner | 5,875,851 | $1.57 | $9.25M | $179.12M | 22 | 2025-04-07 |
| MGTX | Director | 12,531,103 | $11.86 | $148.62M | $15.00M | 3 | 2024-08-14 |
| Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Director | 10,794,876 | $44.96 | $485.34M | $60.00M | 2 | 2024-02-21 |
| VRCA | 10%+ Owner | 709,918 | $5.49 | $3.89M | $27.74M | 2 | 2023-12-29 |
| CARGO Therapeutics, Inc. (CRGX) Delisted | 2,579,502 | $4.47 | $11.53M | $40.00M | 1 | 2023-11-14 | |
| Astria Therapeutics, Inc. (ATXS) Delisted | Director | 1,652,371 | $12.58 | $20.79M | $28.00M | 1 | 2023-10-18 |
| SOLENO THERAPEUTICS INC (SLNO) Delisted | 10%+ Owner | 2,056,955 | $53.01 | $109.04M | $3.13M | 3 | 2023-06-01 |
| VBI Vaccines Inc/BC (VBIV) Delisted | 10%+ Owner | 1,523,061 | $0.07 | $99.5K | $64.91M | 8 | 2023-04-06 |
| Quotient Ltd (QTNT) Delisted | 10%+ Owner | 198,630 | $0.38 | $75.5K | $98.23M | 5 | 2022-11-02 |
| ALBIREO PHARMA, INC. (ALBO) Delisted | 10%+ Owner | 2,216,074 | $44.15 | $97.84M | -$28.52M | 1 | 2022-10-13 |
| LianBio (LIAN) Delisted | Director | 4,330,675 | $0.32 | $1.38M | $1.73M | 1 | 2022-05-27 |
| CRNX | 10%+ Owner | 5,321,032 | $83.85 | $446.17M | $96.78M | 3 | 2022-04-18 |
| AGILE THERAPEUTICS INC (AGRX) Delisted | 10%+ Owner | 10,827 | $1.51 | $16.3K | $48.35M | 7 | 2021-10-15 |
| IsoPlexis Corp (ISO) Delisted | 10%+ Owner | 2,704,587 | $0.76 | $2.06M | $76.50M | 1 | 2021-10-14 |
| RAIN | 10%+ Owner | 2,503,676 | $1.32 | $3.30M | $26.05M | 2 | 2021-10-13 |
| ADMA | 10%+ Owner | 13,262,375 | $8.73 | $115.78M | $45.33M | 5 | 2021-09-30 |
| CYPHERPUNK TECHNOLOGIES INC. (LPTX) Delisted | 10%+ Owner | 847,650 | $1.56 | $1.32M | $10.50M | 2 | 2021-09-28 |
| Landos Biopharma, Inc. (LABP) Delisted | Director | 719,830 | $22.93 | $16.51M | $16.06M | 2 | 2021-08-31 |
| Cerevel Therapeutics Holdings, Inc. (CEREW) Delisted | Director | 5,086,727 | $18.07 | $91.92M | $20.67M | 2 | 2021-08-31 |
| VYNE | 10%+ Owner | 5,483 | $28.56 | $156.6K | $14.04M | 5 | 2021-08-18 |
| NAUT | 6,494,076 | $1.20 | $7.79M | $165.21M | 1 | 2021-06-11 | |
| Nautilus Biotechnology, Inc. (ARYA) Delisted | Director | 489,975 | $11.16 | $5.47M | $14.77M | 2 | 2021-06-03 |
| Prometheus Biosciences, Inc. (RXDX) Delisted | 10%+ Owner | 3,314,032 | $199.92 | $662.54M | $48.45M | 1 | 2021-03-16 |
| SCYX | 10%+ Owner | 276,875 | $3.62 | $1.00M | -$14.12M | 1 | 2021-01-26 |
| Cerevel Therapeutics Holdings, Inc. (CATB) Delisted | Director | 114,100 | $8.54 | $974.4K | $4.73M | 1 | 2020-10-22 |
| Athenex, Inc. (ATNX) Delisted | 10%+ Owner | 676,623 | $0.20 | $137.4K | $175.18M | 14 | 2020-09-14 |
| Lyra Therapeutics, Inc. (LYRA) Delisted | Director | 26,182 | $0.70 | $18.3K | $0 | 1 | 2020-05-06 |
| Kadmon Holdings, Inc. (KDMN) Delisted | 10%+ Owner | 14,636,334 | $9.50 | $139.05M | $15.00M | 1 | 2019-11-18 |
| Dova Pharmaceuticals Inc. (DOVA) Delisted | 10%+ Owner | 3,708,705 | — | — | $49.99M | 10 | 2019-07-11 |
| Motus GI Holdings, Inc. (MOTS) Delisted | 10%+ Owner | 14,035 | $0.00 | $1 | $9.00M | 2 | 2019-07-01 |
| Corium International, Inc. (CORI) Delisted | 10%+ Owner | 5,574,686 | — | — | -$81.53M | 3 | 2018-10-15 |
| AMICUS THERAPEUTICS, INC. (FOLD) Delisted | 10%+ Owner | 20,694,424 | $14.49 | $299.86M | $185.21M | 16 | 2018-10-05 |
| ZOGENIX, INC. (ZGNX) Delisted | 10%+ Owner | 4,070,357 | $26.68 | $108.60M | $45.08M | 3 | 2018-08-14 |
| LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted | 10%+ Owner | 3,613,611 | $6.22 | $22.48M | $4.86M | 1 | 2018-02-20 |
| Global Blood Therapeutics, Inc. (GBT) Delisted | 10%+ Owner | 4,889,066 | $68.49 | $334.85M | $19.95M | 1 | 2017-12-19 |
| Aravive, Inc. (VSAR) Delisted | 10%+ Owner | 624,927 | — | — | $2.93M | 7 | 2017-09-25 |
| TALPHERA, INC. (ACRX) Delisted | 10%+ Owner | 226,686 | $0.86 | $194.9K | -$16.83M | 5 | 2017-06-21 |
| REPROS THERAPEUTICS INC. (RPRX.Z) Delisted | 10%+ Owner | — | — | — | $0 | 1 | 2013-01-30 |
| Aegerion Pharmaceuticals, Inc. (AEGR) Delisted | 10%+ Owner | 2,615,293 | — | — | $3.32M | 2 | 2012-12-05 |
| REPROS THERAPEUTICS INC. (RPRXZ) Delisted | 10%+ Owner | 2,862,560 | — | — | $9.26M | 3 | 2012-05-15 |
| XTLB | 10%+ Owner | 0 | $2.79 | $0 | $74.18M | 7 | 2008-12-03 |
| PENWEST PHARMACEUTICALS CO (PPCO) Delisted | 10%+ Owner | 6,422,846 | — | — | $39.96M | 12 | 2008-11-06 |
| IDEV | 10%+ Owner | 56,300 | $89.47 | $5.04M | -$36.60M | 1 | 2007-01-05 |
Recent Filings
204 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-22 | FRNM | Grant (A) | +16,500,000 | $165.00M | EDGAR |
| 2026-07-10 | LONA | Grant (A) | — | $0 | EDGAR |
| 2026-07-09 | LONA | Grant (A) | — | $0 | EDGAR |
| 2026-06-24 | LONA | Grant (A) | — | $0 | EDGAR |
| 2026-04-13 | LONA | Grant (A) | — | $0 | EDGAR |
| 2026-03-11 | SLDB | Grant (A) | — | $0 | EDGAR |
| 2025-12-23 | LeonaBio, Inc. (ATHA) Delisted | Grant (A) | +5,276,104 | $33.50M | EDGAR |
| 2025-10-22 | ADGM | Buy (P) | — | $0 | EDGAR |
| 2025-06-03 | LeonaBio, Inc. (ATHA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-05-01 | ACRV | Sell (S) | −2,210,301 | -$3.05M | EDGAR |
Showing 1–10 of 204
Page 1 of 21
Next
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.